Symbols / CTMX $5.84 -13.56%
CTMX Chart
About
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna; and clinical trial collaboration and supply agreement with Merck for the evaluation of CX-801 in combination with anti-PD-1 therapy, KEYTRUDA (pembrolizumab). The company was founded in 2008 and is based in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 988.66M |
| Enterprise Value | 1.02B | Income | -20.37M | Sales | 76.20M |
| Book/sh | 0.58 | Cash/sh | 0.81 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | 19.45 | Forward P/E | -11.83 | PEG | — |
| P/S | 12.97 | P/B | 10.03 | P/C | — |
| EV/EBITDA | -48.41 | EV/Sales | 13.33 | Quick Ratio | 2.98 |
| Current Ratio | 3.09 | Debt/Eq | 4.28 | LT Debt/Eq | — |
| EPS (ttm) | 0.30 | EPS next Y | -0.49 | EPS Growth | — |
| Revenue Growth | -98.30% | Earnings | 2026-05-11 | ROA | -10.27% |
| ROE | -35.25% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -42.13% | Profit Margin | -22.79% | Shs Outstand | 169.44M |
| Shs Float | 123.35M | Short Float | 11.53% | Short Ratio | 5.98 |
| Short Interest | — | 52W High | 8.21 | 52W Low | 0.40 |
| Beta | — | Avg Volume | 5.25M | Volume | 8.33M |
| Target Price | $9.00 | Recom | Strong_buy | Prev Close | $6.75 |
| Price | $5.83 | Change | -13.56% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$9.00
Mean price target
2. Current target
$5.71
Latest analyst target
3. DCF / Fair value
$-5.45
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.71
Low
$6.00
High
$10.00
Mean
$9.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | main | Wedbush | Outperform → Outperform | $11 |
| 2026-03-16 | main | HC Wainwright & Co. | Buy → Buy | $17 |
| 2026-03-16 | up | JP Morgan | Neutral → Overweight | $12 |
| 2026-03-09 | reit | Guggenheim | Buy → Buy | $10 |
| 2026-02-04 | main | Cantor Fitzgerald | Overweight → Overweight | $10 |
| 2026-02-04 | main | Barclays | Overweight → Overweight | $10 |
| 2026-01-20 | main | Barclays | Overweight → Overweight | $8 |
| 2026-01-20 | init | Guggenheim | — → Buy | $10 |
| 2026-01-20 | main | Piper Sandler | Overweight → Overweight | $10 |
| 2025-11-11 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-10-21 | main | Barclays | Overweight → Overweight | $6 |
| 2025-09-22 | init | Cantor Fitzgerald | — → Overweight | $6 |
| 2025-07-31 | init | Oppenheimer | — → Outperform | $7 |
| 2025-05-20 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-05-15 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2025-05-15 | up | HC Wainwright & Co. | Neutral → Buy | $5 |
| 2025-04-14 | main | Piper Sandler | Overweight → Overweight | $3 |
| 2025-03-07 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-01-07 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-11 | reit | HC Wainwright & Co. | — → Neutral | — |
- CTMX Stock Pulls Back After 5-Year High: Share Sale Sparks Dilution Fears Despite Wall Street’s 150% Upside Calls - Stocktwits ue, 17 Mar 2026 05
- CTMX Stock Rallies on Strong Phase I Colorectal Cancer Study Data - TradingView ue, 17 Mar 2026 14
- CytomX Therapeutics: Still Some Ways To Go (NASDAQ:CTMX) - Seeking Alpha ue, 17 Mar 2026 18
- CytomX seeks $250M stock sale to fund Varseta-M, pipeline programs - Stock Titan Mon, 16 Mar 2026 20
- CTMX Analyst Rating Update: Wedbush Raises Price Target by 83% | - GuruFocus ue, 17 Mar 2026 13
- CTMX Stock Dives Amidst Public Equity Offering and Financial Report Misses - timothysykes.com ue, 17 Mar 2026 16
- A Look At CytomX Therapeutics (CTMX) Valuation After Varseta M Phase 1 Expansion Data And Earnings Update - simplywall.st ue, 17 Mar 2026 12
- CytomX Therapeutics (NASDAQ:CTMX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat Mon, 16 Mar 2026 16
- CYTOMX THERAPEUTICS Q4 2025 Earnings Preview: Recent $CTMX Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative Fri, 13 Mar 2026 21
- CytomX Therapeutics (CTMX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance Mon, 16 Mar 2026 12
- Experimental colorectal cancer drug shows promise, FDA path eyed for 2026 - Stock Titan Mon, 16 Mar 2026 11
- CTMX: JP Morgan Upgrades CytomX Therapeutics to Overweight, Rais - GuruFocus ue, 17 Mar 2026 08
- CytomX Therapeutics (NASDAQ:CTMX) Given New $11.00 Price Target at Wedbush - MarketBeat ue, 17 Mar 2026 13
- CytomX jumps as investors react to fresh Varseta-M colorectal cancer update alongside FY2025 results - Quiver Quantitative Mon, 16 Mar 2026 14
- Why CTMX Stock Is Soaring 54% Pre-Market Today? - Stocktwits Mon, 16 Mar 2026 11
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 210000 | — | — | Stock Award(Grant) at price 0.00 per share. | MCCARTHY SEAN A. | Chief Executive Officer | — | 2026-02-02 00:00:00 | D |
| 1 | 75000 | — | — | Stock Award(Grant) at price 0.00 per share. | CHU YU-WAYE | Officer | — | 2026-02-02 00:00:00 | D |
| 2 | 90000 | — | — | Stock Award(Grant) at price 0.00 per share. | OGDEN CHRISTOPHER | Chief Financial Officer | — | 2026-02-02 00:00:00 | D |
| 3 | 60000 | — | — | Stock Award(Grant) at price 0.00 per share. | BELVIN MARCIA | Officer | — | 2026-02-02 00:00:00 | D |
| 4 | 20000 | — | — | Stock Award(Grant) at price 0.00 per share. | LESTER RACHAEL | Officer | — | 2026-02-02 00:00:00 | D |
| 5 | 101793 | 461906.0 | — | Sale at price 4.54 per share. | MCCARTHY SEAN A. | Chief Executive Officer | — | 2025-11-06 00:00:00 | D |
| 6 | 12255 | 33381.0 | — | Sale at price 2.69 - 2.95 per share. | OGDEN CHRISTOPHER | Chief Financial Officer | — | 2025-06-16 00:00:00 | D |
| 7 | 13884 | 37334.0 | — | Sale at price 2.69 per share. | BELVIN MARCIA | Officer | — | 2025-06-16 00:00:00 | D |
| 8 | 55511 | 149264.0 | — | Sale at price 2.69 per share. | MCCARTHY SEAN A. | Chief Executive Officer | — | 2025-06-16 00:00:00 | D |
| 9 | 150000 | nan | — | — | MCCARTHY SEAN A. | Chief Executive Officer | — | 2025-06-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.01 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | 26.76M | -4.31M | -98.89M | -113.34M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 31.87M | -569.00K | -99.32M | -115.87M |
| ReconciledDepreciation | 1.77M | 2.17M | 2.44M | 2.71M |
| EBITDA | 26.76M | -4.31M | -98.89M | -113.34M |
| EBIT | 25.00M | -6.48M | -101.33M | -116.04M |
| NetInterestIncome | 7.14M | 9.84M | 1.68M | 255.00K |
| InterestIncome | 7.14M | 9.84M | 1.68M | 255.00K |
| NormalizedIncome | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 31.87M | -569.00K | -99.32M | -115.87M |
| TotalExpenses | 113.11M | 107.70M | 154.50M | 153.35M |
| TotalOperatingIncomeAsReported | 25.00M | -6.48M | -101.33M | -116.04M |
| DilutedAverageShares | 84.75M | 73.81M | 65.74M | 64.15M |
| BasicAverageShares | 84.44M | 73.81M | 65.74M | 64.15M |
| DilutedEPS | 0.38 | -0.01 | -1.51 | -1.30 |
| BasicEPS | 0.38 | -0.01 | -1.51 | -1.30 |
| DilutedNIAvailtoComStockholders | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncomeCommonStockholders | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncome | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncomeIncludingNoncontrollingInterests | 31.87M | -569.00K | -99.32M | -115.87M |
| NetIncomeContinuousOperations | 31.87M | -569.00K | -99.32M | -115.87M |
| TaxProvision | 224.00K | 3.89M | 0.00 | 0.00 |
| PretaxIncome | 32.09M | 3.32M | -99.32M | -115.87M |
| OtherIncomeExpense | -38.00K | -30.00K | 340.00K | -83.00K |
| OtherNonOperatingIncomeExpenses | -38.00K | -30.00K | 340.00K | -83.00K |
| NetNonOperatingInterestIncomeExpense | 7.14M | 9.84M | 1.68M | 255.00K |
| InterestIncomeNonOperating | 7.14M | 9.84M | 1.68M | 255.00K |
| OperatingIncome | 25.00M | -6.48M | -101.33M | -116.04M |
| OperatingExpense | 113.11M | 107.70M | 154.50M | 153.35M |
| ResearchAndDevelopment | 83.38M | 77.68M | 111.65M | 114.19M |
| SellingGeneralAndAdministration | 29.73M | 30.02M | 42.85M | 39.16M |
| GeneralAndAdministrativeExpense | 29.73M | 30.02M | 42.85M | 39.16M |
| OtherGandA | 29.73M | 30.02M | 42.85M | 39.16M |
| TotalRevenue | 138.10M | 101.21M | 53.16M | 37.31M |
| OperatingRevenue | 138.10M | 101.21M | 53.16M | 37.31M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 80.10M | 67.31M | 66.23M | 65.39M |
| ShareIssued | 80.10M | 67.31M | 66.23M | 65.39M |
| TotalDebt | 9.38M | 13.97M | 18.06M | 21.67M |
| TangibleBookValue | -1.99M | -49.12M | -87.58M | -2.43M |
| InvestedCapital | -456.00K | -47.45M | -85.75M | -459.00K |
| WorkingCapital | 21.53M | 27.02M | 84.49M | 232.43M |
| NetTangibleAssets | -1.99M | -49.12M | -87.58M | -2.43M |
| CapitalLeaseObligations | 9.38M | 13.97M | 18.06M | 21.67M |
| CommonStockEquity | -456.00K | -47.45M | -85.75M | -459.00K |
| TotalCapitalization | -456.00K | -47.45M | -85.75M | -459.00K |
| TotalEquityGrossMinorityInterest | -456.00K | -47.45M | -85.75M | -459.00K |
| StockholdersEquity | -456.00K | -47.45M | -85.75M | -459.00K |
| GainsLossesNotAffectingRetainedEarnings | 27.00K | 95.00K | 10.00K | -242.00K |
| OtherEquityAdjustments | 27.00K | 95.00K | 10.00K | -242.00K |
| RetainedEarnings | -691.58M | -723.45M | -722.88M | -623.56M |
| AdditionalPaidInCapital | 691.10M | 675.90M | 637.12M | 623.34M |
| CapitalStock | 1.00K | 1.00K | 1.00K | 1.00K |
| CommonStock | 1.00K | 1.00K | 1.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 120.99M | 249.24M | 346.64M | 339.87M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 35.22M | 93.33M | 194.03M | 262.00M |
| OtherNonCurrentLiabilities | 4.12M | 3.89M | ||
| NonCurrentDeferredLiabilities | 26.86M | 80.05M | 180.06M | 243.94M |
| NonCurrentDeferredRevenue | 26.86M | 80.05M | 180.06M | 243.94M |
| LongTermDebtAndCapitalLeaseObligation | 4.24M | 9.38M | 13.97M | 18.06M |
| LongTermCapitalLeaseObligation | 4.24M | 9.38M | 13.97M | 18.06M |
| CurrentLiabilities | 85.77M | 155.91M | 152.61M | 77.87M |
| CurrentDeferredLiabilities | 67.20M | 132.27M | 121.27M | 40.82M |
| CurrentDeferredRevenue | 67.20M | 132.27M | 121.27M | 40.82M |
| CurrentDebtAndCapitalLeaseObligation | 5.14M | 4.59M | 4.08M | 3.62M |
| CurrentCapitalLeaseObligation | 5.14M | 4.59M | 4.08M | 3.62M |
| PayablesAndAccruedExpenses | 13.43M | 19.06M | 27.26M | 33.44M |
| CurrentAccruedExpenses | 12.34M | 17.60M | 24.45M | 30.62M |
| Payables | 1.09M | 1.46M | 2.81M | 2.82M |
| AccountsPayable | 1.09M | 1.46M | 2.81M | 2.82M |
| TotalAssets | 120.53M | 201.79M | 260.89M | 339.41M |
| TotalNonCurrentAssets | 13.23M | 18.86M | 23.79M | 29.11M |
| OtherNonCurrentAssets | 1.09M | 1.00M | 944.00K | 1.82M |
| GoodwillAndOtherIntangibleAssets | 1.53M | 1.68M | 1.82M | 1.97M |
| OtherIntangibleAssets | 583.00K | 729.00K | 875.00K | 1.02M |
| Goodwill | 949.00K | 949.00K | 949.00K | 949.00K |
| NetPPE | 10.60M | 16.18M | 21.02M | 25.32M |
| AccumulatedDepreciation | -16.23M | -14.69M | -14.37M | -13.83M |
| GrossPPE | 26.83M | 30.87M | 35.39M | 39.15M |
| Leases | 2.00M | 1.98M | 1.74M | 1.74M |
| ConstructionInProgress | 0.00 | 368.00K | 705.00K | 308.00K |
| OtherProperties | 8.14M | 12.22M | 15.95M | 19.36M |
| MachineryFurnitureEquipment | 16.69M | 16.30M | 17.00M | 17.75M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 107.31M | 182.94M | 237.10M | 310.30M |
| OtherCurrentAssets | 3.58M | 5.00M | 7.47M | 4.29M |
| PrepaidAssets | 4.29M | |||
| Receivables | 3.10M | 3.43M | 35.99M | 790.00K |
| AccountsReceivable | 3.10M | 3.43M | 35.99M | 790.00K |
| CashCashEquivalentsAndShortTermInvestments | 100.62M | 174.51M | 193.65M | 305.23M |
| OtherShortTermInvestments | 62.57M | 157.34M | 0.00 | 99.70M |
| CashAndCashEquivalents | 38.05M | 17.17M | 193.65M | 205.53M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -86.54M | -56.88M | -112.53M | -120.64M |
| IssuanceOfCapitalStock | 6.91M | 0.00 | 107.71M | |
| CapitalExpenditure | -310.00K | -840.00K | -1.74M | -1.61M |
| IncomeTaxPaidSupplementalData | 0.00 | |||
| EndCashPosition | 39.08M | 18.09M | 194.57M | 206.45M |
| BeginningCashPosition | 18.09M | 194.57M | 206.45M | 192.78M |
| ChangesInCash | 20.99M | -176.48M | -11.88M | 13.67M |
| FinancingCashFlow | 7.52M | 30.23M | 648.00K | 110.21M |
| CashFlowFromContinuingFinancingActivities | 7.52M | 30.23M | 648.00K | 110.21M |
| ProceedsFromStockOptionExercised | 613.00K | 30.23M | 648.00K | 2.50M |
| NetCommonStockIssuance | 6.91M | 0.00 | 107.71M | |
| CommonStockIssuance | 6.91M | 0.00 | 107.71M | |
| InvestingCashFlow | 99.70M | -150.67M | 98.26M | 22.49M |
| CashFlowFromContinuingInvestingActivities | 99.70M | -150.67M | 98.26M | 22.49M |
| NetInvestmentPurchaseAndSale | 100.01M | -149.83M | 100.00M | 24.10M |
| SaleOfInvestment | 255.50M | 275.00M | 100.00M | 124.00M |
| PurchaseOfInvestment | -155.49M | -424.83M | 0.00 | -99.90M |
| NetPPEPurchaseAndSale | -310.00K | -840.00K | -1.74M | -1.61M |
| PurchaseOfPPE | -310.00K | -840.00K | -1.74M | -1.61M |
| OperatingCashFlow | -86.23M | -56.03M | -110.79M | -119.03M |
| CashFlowFromContinuingOperatingActivities | -86.23M | -56.03M | -110.79M | -119.03M |
| ChangeInWorkingCapital | -126.42M | -62.51M | -30.65M | -22.44M |
| ChangeInOtherWorkingCapital | -118.25M | -89.01M | 16.57M | -33.95M |
| ChangeInOtherCurrentAssets | -56.00K | 874.00K | 1.27M | |
| ChangeInPayablesAndAccruedExpense | -9.93M | -8.47M | -9.72M | 7.42M |
| ChangeInAccruedExpense | -9.63M | -7.04M | -9.78M | 7.56M |
| ChangeInPayable | -297.00K | -1.43M | 68.00K | -139.00K |
| ChangeInAccountPayable | -297.00K | -1.43M | 68.00K | -139.00K |
| ChangeInPrepaidAssets | 1.43M | 2.42M | -3.18M | 2.81M |
| ChangeInReceivables | 329.00K | 32.55M | -35.20M | 8.00K |
| ChangesInAccountReceivables | 329.00K | 32.55M | -35.20M | 8.00K |
| OtherNonCashItems | 4.08M | 3.73M | 3.41M | 3.13M |
| StockBasedCompensation | 7.67M | 8.56M | 13.12M | 13.17M |
| AssetImpairmentCharge | 106.00K | 0.00 | 254.00K | 0.00 |
| AmortizationOfSecurities | -5.31M | -7.42M | -52.00K | 272.00K |
| DepreciationAmortizationDepletion | 1.77M | 2.17M | 2.44M | 2.71M |
| DepreciationAndAmortization | 1.77M | 2.17M | 2.44M | 2.71M |
| AmortizationCashFlow | 146.00K | 146.00K | 146.00K | 146.00K |
| AmortizationOfIntangibles | 146.00K | 146.00K | 146.00K | 146.00K |
| Depreciation | 1.62M | 2.03M | 2.30M | 2.56M |
| NetIncomeFromContinuingOperations | 31.87M | -569.00K | -99.32M | -115.87M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CTMX
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|